Skip to main content

CORRECTION article

Front. Oncol., 13 September 2023
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1278074
This article is part of the Research Topic Tumor Accommodation: The Importance of the Niche in Neurological Tumors View all 5 articles

Corrigendum: Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: a case report and review of the literature

This article is a correction to:

  1. Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: A case report and review of the literature

    1. Read original article
Jacopo Lolli&#x;Jacopo Lolli1†Francesca Tessari&#x;Francesca Tessari1†Franco BertiFranco Berti1Marco Fusella,Marco Fusella1,2Davide Fiorentin,Davide Fiorentin1,2Davide BimbattiDavide Bimbatti3Umberto BassoUmberto Basso3Fabio Busato,*&#x;Fabio Busato1,2*†
  • 1Radiotherapy Unit, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy
  • 2Department of Radiation Oncology, Abano Terme Hospital, Padua, Italy
  • 3Medical Oncology 1, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy

A Corrigendum on
Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: a case report and review of the literature

by Lolli J, Tessari F, Berti F, Fusella M, Fiorentin D, Bimbatti D, Basso U and Busato F (2023) Front. Oncol. 13:1136300. doi: 10.3389/fonc.2023.1136300

In the published article, there was an error in the Funding statement as it was not specified that this research was funded by the Italian Ministry of Health Ricerca Corrente. The correct Funding statement appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Funding

This research was funded by Italian Ministry of Health Ricerca Corrente.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: cabozantinib, radionecrosis (RN), stereotacic radiation, immunotherapy, radiosurgery

Citation: Lolli J, Tessari F, Berti F, Fusella M, Fiorentin D, Bimbatti D, Basso U and Busato F (2023) Corrigendum: Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: a case report and review of the literature. Front. Oncol. 13:1278074. doi: 10.3389/fonc.2023.1278074

Received: 15 August 2023; Accepted: 29 August 2023;
Published: 13 September 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Lolli, Tessari, Berti, Fusella, Fiorentin, Bimbatti, Basso and Busato. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Fabio Busato, fabio1988busato@gmail.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.